Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–914.
   PubMed Web of Science ®Google Scholar
• Bolla M, Maingon P, Carrie C, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748–1756.
   PubMed Web of Science ®Google Scholar
• Garisto JD, Klotz L. Active surveillance for prostate cancer: how to do it right. Oncology. 2017;31(5):333–340, 345.
   PubMed Web of Science ®Google Scholar
• Hendriksen PJ, Dits NF, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 2006 May 15;66(10):5012–5020.
   PubMedGoogle Scholar
• Conteduca V, Gurioli G, Brighi N, et al. Plasma Androgen Receptor in Prostate Cancer. Cancers (Basel). 2019 Nov 4;11(11):1719.
   Web of Science ®Google Scholar
• Helsen C, Van den Broeck T, Voet A, et al. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014;21(4):T105–T118.
   PubMed Web of Science ®Google Scholar
• Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen- deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727–737.
   PubMed Web of Science ®Google Scholar
• Duchesne GM, Woo HH, King M, et al. Health-related quality of life for immediate versus (vs) delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomized, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017;18(9):1192–1201.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005;96(7):985–989.
   PubMed Web of Science ®Google Scholar
• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642.
   PubMed Web of Science ®Google Scholar
• HI S, Solo K, Valant J, et al. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One. 2015;10(10):e0139440. [Incidence and prevalence of nmCRPC].
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. [Pivotal trial of enzalutamide in mCRPC after docetaxel: the AFFIRM trial].
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474. [Pivotal trial of enzalutamide in nmCRPC - the PROSPER trial].
   PubMed Web of Science ®Google Scholar
• Armstrong A, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986.
   PubMed Web of Science ®Google Scholar
• Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11(11):2167–2172.
   PubMed Web of Science ®Google Scholar
• Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide vs flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex combination study group. Urology. 1995;45(5):745–752.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–424.
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int. 2005;96(6):791–795.
   PubMed Web of Science ®Google Scholar
• Klotz L, Drachenberg D, Singal R, et al. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian urology research consortium study. Prostate Cancer Prostatic Dis. 2014;17(4):320–324.
   PubMed Web of Science ®Google Scholar
• Small EJ, Baron AD, Fippin L, et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997;157(4):1204–1207.
   PubMed Web of Science ®Google Scholar
• Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest oncology group trial (SWOG 9426). Cancer. 2008;112(11):2393–2400.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418. [Pivotal trial of apalutamide in nmCRPC].
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Fizazi K, Saad F, et al. Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). N Engl J Med. 2020;382(23):2197–2206.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore ND, Tammela T, et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(suppl; abstr 5514):5514.
   Google Scholar
• Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30(11):1813–1820. .
   PubMed Web of Science ®Google Scholar
• Xie W, Regan MM, Buyse M, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35(27):3097–3104.
   PubMed Web of Science ®Google Scholar
• Smith MR, Cook R, Lee KA, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117:2077–2085.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800–3806.
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 4.2019 Prostate Cancer. [cited 2020 Jan 8]. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–1503.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Smith MR, Tombal B, et al. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer. 2018;16(5):332–340.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, NY). 2009;324(5928):787–790.
   Google Scholar
• von Klot CA, Kuczyk MA, Merseburger AS. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the post-chemotherapy setting. Eur Urol. 2014;65(1):258–259.
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33–39.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, Ouatas T, Krauwinkel W, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54(10):1043–1055.
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437–1446.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the Phase III PREVAIL study. Eur Urol. 2017;71(2):151–154.
   PubMed Web of Science ®Google Scholar
• Evans CP, Higano CS, Keane T, et al. The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naïve metastatic castration-resistant prostate cancer. Eur Urol. 2016;70(4):675–683.
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• XTANDI (enzalutamide) capsules for oral use. Prescribing information. Astellas Pharma Inc; 2019 [cited 2020 Aug 4]. www.astellas.us/docs/12A005-ENZ-WPI.PDF.
   Google Scholar
• Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011;71:480–488.
   PubMed Web of Science ®Google Scholar
• Shore ND, Saltzstein D, Sieber P, et al. Results of a real-world study of enzalutamide and abiraterone acetate with prednisone tolerability (REAAcT). Clin Genitourin Cancer. 2019 Dec;17(6):457–463.
   PubMed Web of Science ®Google Scholar
• Zurth C, Sandman S, Trummel D, et al. Higher blood–brain barrier penetration of [14C] apalutamide and [14C] enzalutamide compared to [14C] darolutamide in rats using whole-body autoradiography. J clin oncol. 2019 March 01;37(7_suppl):156.
   Web of Science ®Google Scholar
• Zurth C, Sandman S, Trummel D, et al. Blood-brain barrier penetration of [14C] darolutamide compared with [14C] enzalutamide in rats using whole body autoradiography. J clin oncol. 2018 February 20;36(6_suppl):345.
   Web of Science ®Google Scholar
• Higano CS, Beer TM, Taplin ME, et al. Long-term safety and antitumor activity in the phase 1-2 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol. 2015;68(5):795–801.
   PubMed Web of Science ®Google Scholar
• Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34(18):2098–2106.
   PubMed Web of Science ®Google Scholar
• Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153–163.
   PubMed Web of Science ®Google Scholar
• Slovin S, Clark W, Carles J, et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. JAMA Oncol. 2018;4(5):702–706.
   PubMed Web of Science ®Google Scholar
• Azad A, Saad F, Chowdhury S, et al. Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomized clinical trials [abstract no. 102]. Asia Pac J Clin Oncol. 2017;13(Suppl 1):41.
   Google Scholar
• Wallis CJD, Chandrasekar T, Goldberg H, et al. Advanced androgen blockage in nonmetastatic castration-resistant prostate cancer: an indirect comparison of apalutamide and enzalutamide. Eur Urol Oncol. 2018 Aug;1(3):238–241.
   PubMed Web of Science ®Google Scholar
• Altavilla A, Di Maio M, Tucci M, et al. Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): A network meta-analysis of randomized controlled trials (RCT). ESMO meeting abstracts. Ann Oncol. 2019;30(Supplement_5):868P.
   Google Scholar
• Burgio SL, Conteduca V, Rudnas B, et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(1):39–43.
   PubMed Web of Science ®Google Scholar
• Conteduca V, Burgio SL, Menna C, et al. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate. 2014;74(16):1691–1696.
   PubMed Web of Science ®Google Scholar